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Purpose: High intensity focused ultrasound (HIFU) provides a non-invasive salvage treatment
option for patients with recurrence after external beam radiation therapy (EBRT). As part of EBRT
the prostate is frequently implanted with permanent fiducial markers. To date, the impact of these
markers on subsequent HIFU treatment is unknown. The objective of this work was to systematically
investigate, using computational simulations, how these fiducial markers affect the delivery of HIFU
treatment.
Methods: A series of simulations was performed modelling the propagation of ultrasound pressure
waves in the prostate with a single spherical or cylindrical gold marker at different positions and
orientations. For each marker configuration, a set of metrics (spatial-peak temporal-average intensity,
focus shift, focal volume) was evaluated to quantify the distortion introduced at the focus. An analyti-
cal model was also developed describing the marker effect on the intensity at the focus. The model
was used to examine the marker's impact in a clinical setting through case studies.
Results: The simulations show that the presence of the marker in the pre-focal region causes reflec-
tions which induce a decrease in the focal intensity and focal volume, and a shift of the maximum
pressure point away from the transducer's focus. These effects depend on the shape and orientation of
the marker and become more pronounced as its distance from the transducer's focus decreases, with
the distortion introduced by the marker greatly increasing when placed within 5 mm of the focus.
The analytical model approximates the marker's effect and can be used as an alternative method to
the computationally intensive and time consuming simulations for quickly estimating the intensity at
the focus. A retrospective review of a small patient cohort selected for focal HIFU after failed EBRT
indicates that the presence of the marker may affect HIFU treatment delivery.
Conclusions: The distortion introduced by the marker to the HIFU beam when positioned close to
the focus may result in an undertreated region beyond the marker due to less energy arriving at the
focus, and an overtreated region due to reflections. Further work is necessary to investigate whether
the results presented here justify the revision of the patient selection criteria or the markers’ place-
ment protocol. © 2016 The Authors. Medical Physics published by Wiley Periodicals, Inc. on behalf
of American Association of Physicists in Medicine. [https://doi.org/10.1002/mp.12044]
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1. INTRODUCTION
Prostate cancer is the most commonly occurring male cancer
and the second leading cause of cancer-related death in men
in the European Union (EU) and the United States of Amer-
ica (USA).1,2 More specifically, in 2012 of all reported cancer
cases in men, prostate cancer accounted for 24.1% in the EU,
with a 10% mortality rate, and 28.3% in the USA, with a
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9.4% mortality.1 According to the American Cancer Society,
these rates are estimated to continue in 2016.3 These figures
differ when viewed based on worldwide data, where prostate
cancer appears as the second most diagnosed cancer in men
with 1.1 million diagnosed cases in 2012 (14.8%) and as the
fifth cause of cancer-related death with 307 thousand deaths
(6.6%).1,4 Despite the lower incidence and mortality rates from
worldwide data, prostate cancer is still one of the major malig-
nancies affecting hundreds of thousands of men each year and
improving its diagnosis and treatment is of great importance.
There is a range of available options for treating prostate
cancer with some of them having a curative intent and others
palliative. Selecting an appropriate therapy depends on sev-
eral factors, such as the stage of the tumor, biochemical indi-
cators (e.g. prostate specific antigen value), Gleason score,
other associated diseases, the patient’s age and life expec-
tancy, as well as the patient’s personal preference.5 For local-
ized or locally advanced prostate cancer, recommended
treatments for primary therapy include active surveillance,
radical prostatectomy (RP), external beam radiation therapy
(EBRT) and temporary (high-dose rate) or permanent (low-
dose rate) brachytherapy (BT) with or without additional
EBRT. These treatments may be offered independently or in
combination with hormonal therapy (androgen deprivation
therapy). In recent years, new minimally invasive modalities
have emerged and provide alternative treatment options with
the most notable being high intensity focused ultrasound
(HIFU) and cryosurgery.5–7
EBRT is an effective primary therapy option with good sur-
vival rates reported.8–10 It is estimated that 12–24% of patients
diagnosed with localized prostate cancer receive EBRT as a pri-
mary treatment.11,12 Although numbers may differ depending on
the definition of failure used, in approximately 30% of these
patients their cancer will recur8,13–16 with some studies reporting
even higher rates.14,17–20 For patients with local recurrence after
EBRT, depending on life expectancy and tumor progression, an
alternative (salvage) therapy may still be appropriate in order to
limit further progression of the disease and metastasis.14,20 The
four major options for re-treatment available after EBRT fail-
ure are salvage RP, salvage BT, salvage cryosurgery and salvage
HIFU.15,16,19,21 Amongst these methods, salvage RP is the most
established treatment with good oncological outcomes.15 How-
ever, it is associated with high morbidity,14–16,18,19,22,23 thus,
doctors may be reluctant to recommend it, especially for
patients with a short life expectancy.14–16,19 The other three
modalities provide a less invasive alternative, with HIFU offer-
ing the least invasive approach.20
HIFU has been the subject of many studies indicating its
potential as a primary treatment for locally confined prostate
cancer.24 Accurately determining the efficacy of this modality
is not easy, especially due to the inconsistency in reporting
biochemical failure and due to the absence of long-term
oncological outcomes.25,26 As a result and despite already
being in use in many centers across the world, HIFU is still
classified as an experimental treatment, for example, by the
European Association of Urologists (EAU).6 Nonetheless,
some studies report encouraging results for primary HIFU
treatment with low mortality rate, high metastasis-free sur-
vival rate, and acceptable side-effects comparable to other
minimally invasive modalities.24,26
Currently, only a limited number of studies report on the
efficacy and safety of HIFU as a salvage therapy after failure
of EBRT.5,15,27 Additionally, no prospective randomized tri-
als have been reported.27 Consequently, comparison of HIFU
with other conventional salvage modalities is difficult. Most
of the published investigations are retrospective stud-
ies,14,17,20,28,29 with only a few prospective series
reported.5,19,23 The majority of these studies report good local
cancer control, indicating the potential of HIFU as an effec-
tive salvage therapy for low- and intermediate-risk patients.
In some studies, the rate of complications reported is high,
with some adverse effects comparable to the other salvage
therapies. This presents a limitation for the use of HIFU as a
salvage therapy.23 However, it is interesting to observe that in
those studies where new refined treatment parameters were
introduced, dedicated to post-radiation salvage-HIFU treat-
ments, the side-effects were significantly reduced.14,19,23
Salvage treatment in a previously irradiated prostate is
technically challenging, and higher rates and more severe side
effects are expected. However, the positive effect of the new
treatment parameters introduced in some of the studies for
post-EBRT salvage-HIFU demonstrates that there is signifi-
cant opportunity for improving both the delivery of salvage-
HIFU treatment as well as patient selection. An aspect of sal-
vage HIFU that has been overlooked so far, and which may
affect the treatment’s safety and efficacy as well as patient
selection, is the presence of fiducial markers that are increas-
ingly introduced in the prostate as part of modern image-
guided radiotherapy (IGRT).30,31 To the best of our knowl-
edge, there are no studies investigating the effect of these
markers on the delivery of salvage-HIFU after EBRT, with
the exception of a small number of studies reporting on the
effect of permanent BT seeds on HIFU.32,33 The purpose of
this work was to perform an extensive quantitative investiga-
tion of the effect of fiducial markers on the propagation and
focusing of the ultrasound (US) waves when the beam path is
obstructed by an EBRT fiducial marker.
The fiducial markers are introduced in the prostate in
order to improve the accuracy of EBRT. They facilitate the
localization of the prostate, enable motion and deformation
tracking and act as reference points for distance measure-
ments as well as for registering images obtained from differ-
ent imaging modalities.30,31,34,35 Typically 3 radio-opaque
markers are implanted in the prostate before the patient
undergoes EBRT planning and remain permanently in the
prostate after the completion of the treatment.36,37 The mark-
ers are placed within the prostate gland using a transperineal
or transrectal approach with a needle holding one or two
markers, under the guidance of transrectal ultrasound (TRUS)
in a procedure similar to that of a biopsy.36,38 Although this
may differ between hospitals, the markers are typically placed
in the prostate base, mid-gland, and apex at a distance of
approximately 2 cm from each other and at least a 15 angle
between any fiducial triplets.36,39,40 Consequently, only a
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single marker is likely to be encountered by the HIFU beam
for any individual sonication.
There is a large range of commercially available markers
made from a variety of materials in different shapes and
dimensions.30,34,35,41 The most commonly used markers are
made of gold, making them visible in a variety of imaging
modalities, and have a cylindrical shape with their surface
appropriately shaped to minimize migration.30 Although less
frequent, spherical gold markers are also utilized.42,43 These
two shapes facilitate their insertion using a needle. More
recently, new types of markers have emerged that offer some
advantages but have yet to gain wide popularity. There are
three notable examples. First, carbon fiducials, which offer
better visibility and produce less artefacts on computed
tomography (CT) images. Second, metallic coils and strings
of markers on an absorbable strand, which may offer better
stability and localization since they stretch across the whole
gland. Finally, a new family of markers with a transponder
built-in to allow wireless tracking of their position in
real-time without the need for additional imaging of the
prostate.30
This work investigates the effect of a single gold marker
on the HIFU beam using numerical simulations based on a
model of the prostate containing a spherical or cylindrical
fiducial. For each marker shape, a series of simulations was
performed on a high performance computer (HPC) cluster to
evaluate the propagation of the HIFU beam in the prostate
when its path is obstructed by a single gold marker. The sim-
ulations used the open-source k-Wave44,45 toolbox developed
by our group for accurate modelling of the propagation of US
waves. The simulation results were also used to verify an ana-
lytical model developed for approximating the effect of the
marker on the intensity at the focus and for identifying a
region within which the marker has a significant impact on
the focusing. The study was performed in silico for several
reasons. First, computer simulations provide an effective and
low-cost method for investigating the key factors at play in
HIFU therapy delivery in a way that would be impractical,
costly, and possibly unethical in patients. Second, simulations
give access to a complete characterization of the acoustic
field parameters that are not accessible from an experiment.
Knowledge of these parameters is critical to understand and
quantify the effect of the markers.
2. METHODS
2.A. Clinical HIFU systems for prostate cancer
There are three approved transrectal HIFU treatment sys-
tems dedicated to prostate cancer and one transurethral device
currently in clinical trials. The transrectal systems are the
Sonablate 500 (SonaCare Medical LLC, Charlotte, NC,
USA), the Ablatherm II (EDAP TMS, Vaulx-en-Velin,
France), and the Focal One also developed by EDAP TMS.
The operation of these systems is based on similar principles.
They all deliver the treatment using a probe with an inte-
grated HIFU and imaging transducer, which is used
transrectally under US guidance to induce ablation of the tar-
geted region.24 On the other hand, the TULSA-PRO (PRO-
FOUND MEDICAL Corp., Toronto, Canada) delivers
transurethral ultrasound ablation of prostate cancer under
magnetic resonance imaging (MRI) guidance.46
The transducer model used in this work nominally fol-
lowed the specifications of the Sonablate 500 (SonaCare
Medical). This system is currently in use at University Col-
lege London Hospital (UCLH).47 The Sonablate 500 consists
of a console, a transrectal probe, and a cooling and degasing
module. The transducer is held at the tip of the probe by a
motorized system that allows it to move in the longitudinal
and transverse direction with a 90 degree treatment win-
dow.48 The transducer module itself consists of two dual-
mode (splitbeam) transducers stacked back-to-back capable
of both imaging at 6.3 MHz and treatment at 4 MHz. To
achieve this dual-mode operation, each side of the transducer
consists of two elements: a circular element at its center, ded-
icated to imaging, surrounded by an annular element, used
for treatment. Each side is manufactured with a different cur-
vature resulting in two fixed focal lengths (30 mm and
40 mm) by means of geometric focusing. This allows the
whole prostate gland to be treated using a single probe and
without the need for electronic beam steering. The current
dimensions of the transducer are 22 mm by 30 mm, noting
that earlier revisions of the system used a 22 mm by 35 mm
transducer. The dimensions of the earlier revision are fol-
lowed in this work.
During treatment, the ablation is given in blocks and can
be applied to the whole gland or focally to only the cancerous
lesion within the prostate. The ablated volume is pseudoellip-
soidal and its precise location is determined by the focal
length of the transducer. For each sonication, the ablated vol-
ume is on the order of 3 3 10 mm3. Multiple sonications
with slight overlap move sequentially through the prostate
with 3 s ‘on’ time exposures and 6 s ‘off’ time exposures.
The prostate is divided into six blocks, left and right with cor-
responding anterior, middle, and posterior blocks. The
40 mm focal length is used for anterior and middle block
treatment and the 30 mm probe for posterior block treatment.
Tissue destruction is produced by thermal, mechanical, and
cavitation effects to produce a clearly demarcated region of
coagulative necrosis.
2.B. Simulation setup
The simulations were performed using the open-source k-
Wave Toolbox.44 This solves a generalized version of the
Westervelt equation accounting for the combined effects of
nonlinearity, heterogeneous material properties, and acoustic
absorption following a frequency power law. The transducer
geometry was assumed to be a spherical section with
width Wt ¼ 22 mm, length Lt ¼ 35 mm, focal length
Rt ¼ 40 mm and without an imaging element included. The
simulations were performed using a regular Cartesian mesh
and the transducer was defined in the grid as a simply-
connected sphere with a single grid-point thickness truncated
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to the appropriate width and height. The discretized trans-
ducer model is shown in Fig. 1. The transducer was driven by
a f0 ¼ 1=T ¼ 4 MHz sinusoidal input signal, with surface
pressure p0 given by
p0 ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2Iavq0c0
p
: (1)
Here q0 and c0 are, respectively, the density and sound speed
of the background medium and Iav ¼ 4 W/cm
2 is the time-
averaged source surface intensity. The value of Iav was
selected such that the focal intensity is of the order of magni-
tude reported for the Sonablate 500 (1000–2000 W/cm2).49,50
The total duration of the input signal was 60 ls, which
was equal to the total simulation time and long enough to
ensure the pressure had reached steady-state. To ensure stabil-
ity, a smaller time step dt was used for the simulations in
which a marker was introduced in the grid.45 The time step
for the homogeneous case (without marker) was given by
dt ¼ 0:33dx=c0, and for the heterogeneous case (with mar-
ker) by dt ¼ 0:066dx=c0, where dx is the spatial grid-spa-
cing. As a result, the total number of time steps was 5 times
higher for the heterogeneous simulations.
The physical dimensions of the simulation volume were
ðLx; Ly; LzÞ ¼ ð44:7; 29:4; 60:0Þ mm. This was discretized to
a regular Cartesian grid with dimensions ðNx;Ny;NzÞ, which
included a LPML ¼ 20 grid-points (pt) perfectly matched
layer (PML) at either end of each coordinate axis.51 The grid
spacing was uniform along all three coordinate axes and was
defined according to dx ¼ dy ¼ dz ¼ Lz=ðNz  2LPMLÞ.
The background medium was assigned the material proper-
ties of the prostate (density: q0 ¼ 1050 kg/m
3 and sound-
speed: c0 ¼ 1578 m/s), and the spherical or cylindrical
volume occupied by the marker was assigned the properties
of gold (density: qm ¼ 19300 kg/m
3 and sound-speed:
cm ¼ 3240 m/s). Reference simulations were also performed
without the inclusion of a marker in order to record the char-
acteristics of an uninterrupted HIFU beam. Both sets of simu-
lations were nonlinear (nonlinearity parameter: B/A = 6.75)
and accounted for absorption following a frequency power
law of the form a0f
y0 where a0 ¼ 0:5 dB MHz
y0cm1 and
y0 ¼ 1:1.
2.C. Marker placement
To investigate the effect of fiducials on the propagation
and focusing of the HIFU beam, each simulation included a
single spherical or cylindrical gold marker positioned at dif-
ferent coordinates, with the position of the transducer kept
fixed across all simulations. The spherical marker had a
3 mm diameter, whereas the cylindrical had a 3 mm height
and 1 mm diameter. The simulated positions for each marker
shape are shown in Fig. 2.
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FIG. 1. The discretized transducer model used in the simulations shown in
3D. [Color figure can be viewed at wileyonlinelibrary.com]
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FIG. 2. The positions and orientations simulated for (a) the spherical markers with 3 mm diameter and (b)–(d) the cylindrical markers with 1 mm diameter
and 3 mm height. The simulated positions are shown superimposed on the maximum pressure field of a homogeneous medium. The markers were placed
on the zx plane which includes the transducer’s focal-point mf , indicated by the star-like marker. The cross-section of the transducer is also indicated at the
top of each figure. [Color figure can be viewed at wileyonlinelibrary.com]
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In order to reduce the number of simulations performed, the
center positions of the markers were limited to the xz plane at
y ¼ Ny=2. This plane includes the center of the focal region
which was expected at approximately mf ¼ ðNx=2;
Ny=2; bRt=dzcÞ, where m is a 3-dimensional (3D) vector
denoting the coordinates of any point in the grid. If the plane is
further divided into four quadrants with the origin at the focal
point, the simulated positions were limited to the top-right and
bottom-left quadrant as shown in Fig. 2(a). The choice of limit-
ing the tested marker positions into two quadrants on a single
plane was based on the assumption that any observed effect
will be approximately symmetric about the beam axis. Both
types of markers were positioned radially along the axes con-
necting the focal point to the transducer. The distance between
markers along each axis, as well as the angle between succes-
sive axes, were kept constant. Hence, the markers can be
grouped either with respect to the angle of the radial axis from
the beam axis (see Fig. 5(f) inset), or with respect to their dis-
tance from the focal-point (see Fig. 5(c) inset).
2.D. Quantifying marker effect
To systematically evaluate the effect of a single marker on
the focusing of the HIFU beam, four metrics were selected
and evaluated using the simulation results for each marker
position. These metrics were later compared to the corre-
sponding quantities obtained from a homogeneous simulation
without a marker.
The first quantity evaluated was defined to measure how
much the focus has shifted from its intended position. Let
mref denote the coordinates of the maximum-pressure point
extracted from a homogeneous simulation without a marker.
This point will be referred as the focal-point, or simply the
focus. Let also mmax denote the coordinates of the maximum-
pressure point extracted from a heterogeneous simulation
with a marker. Then, the focus-shift was calculated using
dshift ¼ kmmax mrefk (2)
which is the Euclidean distance between mmax and mref .
The next set of metrics were based on the spatial-peak
temporal-average (SPTA) intensity (Ispta). For each simulated
marker position, this quantity was evaluated both at the coor-
dinates of the homogeneous focus (mref ) and the coordinates
of the maximum-pressure point (mmax). The two scalar values
(IsptaðmrefÞ  Ifocus and IsptaðmmaxÞ  Imax) were obtained
using
IsptaðmÞ ¼
1
nT
Z nT
0
p2ðm; tÞ
q0c0
dt (3)
where p(m, t) is the pressure time series at the coordinates of
the maximum-pressure point (m ¼ mmax) or the focus
(m ¼ mref ), n≥1 is a positive integer and T is the period of
the driving frequency. Evaluating Eq. (3) at mref for a homo-
geneous simulation gives the SPTA intensity of an uninter-
rupted beam denoted as Ihom. Comparison of Ifocus and Imax
with Ihom provides an indication of how much energy is redis-
tributed due to the presence of the marker. It is noted that
henceforth intensity will always refer to SPTA intensity.
Finally, to measure how the size of the focal region
changes when the marker is included compared to the homo-
geneous simulation, the 6 dB focal volume was calculated
for each simulation. This was obtained using
Vf ¼ N dx dy dz (4)
where N is the number of voxels for which IsptaðmÞ was
greater than 50% of Imax (the maximum intensity for that sim-
ulation). As the reference intensity changes for each simula-
tion, this metric does not give a direct indication of the
ablation volume. However, taken together with Imax, it pro-
vides a useful indication of the volume over which the acous-
tic energy is distributed.
The focusing metrics were evaluated using the final five
cycles of the pressure time-series and excluded the pressure
time-series recorded within the marker volume. In order to
reduce the size of the output from each simulation, the pres-
sure time-series was recorded within a sub-region of the grid
(see Table I) centered at the focal-point of the transducer
(mref ). Even with this restriction in place, the output file size
was approximately 0.5 TB per simulation.
TABLE I. Computational cost in terms of memory and simulation time associated with each grid-size.
Grid-size (pt3)
Homogeneous simulations Heterogeneous simulations
RAMa (GB) Inputb (MB) Outputb (GB)
Timec
(dd:hh:mm) RAMa (GB) Inputb (GB) Outputb (GB)
Timec
(dd:hh:mm)
S1 ¼ 384 256 512 10.5 2.9 0.7 00:00:10 11.9 4.1 2.0 00:00:39
S2 ¼ 768 512 1024 37.2 20.3 8.5 00:02:06 48.5 28.3 30.3 00:10:16
S3 ¼ 1152 768 1536 108.4 70.0 37.1 00:12:01 141.7 95.8 144.9 02:13:23
S4 ¼ 1536 1024 2048 246.4 165.2 108.4 01:16:07 331.9 225.9 445.9 08:11:38
S5 ¼ 2304 1536 3072 830.7 554.6 508.7 06:19:51 — — — —
aRandom access memory (RAM) requirements at each grid-size. MB = 220 bytes, GB = 230 bytes.
bSize of the input and output files of the simulation. At S1 the pressure is recorded in the output within a 96 96 192pt
3 volume. These dimensions increase proportion-
ally to the grid-size, except from S5 where a smaller volume was used.
cTime required for completing a single simulation. May vary depending on the HPC’s workload. (dd:hh:mm) = (days:hours:minutes).
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2.E. Convergence test for grid-size selection
The grid-size required for the simulations was estab-
lished using a convergence test. In particular, because of
nonlinear wave propagation, some of the energy from the
fundamental frequency of the driving signal is shifted to
higher harmonics. For these harmonics to be captured by
the model, the physical domain must be appropriately dis-
cretized. For the numerical method used, waves can be
accurately propagated close to the Nyquist limit of two
grid-points per minimum wavelength. However, the energy
at higher frequency harmonics is not known a priori. As a
result, the choice of the grid-size will determine the num-
ber of harmonics that can be represented on the grid and
thus the accuracy with which the nonlinearity is captured.
On the other hand, increasing the grid-size translates to
higher computational requirements in terms of memory and
simulation time. Therefore, the selected grid-size was a
compromise between the number of supported harmonics
and the associated computational cost.
To determine the appropriate grid-size, homogeneous
and heterogeneous simulations were performed at increas-
ing grid dimensions. The configuration of these simulations
was as described in Section 2, with the heterogeneous sim-
ulation including a single spherical gold marker between
the focal-point and the transducer at (0,0,8) mm. Here, the
marker position is reported with respect to the coordinates
of the focal point. The grid-sizes tested are shown in
Table I, noting that a heterogeneous simulation at S5 was
not performed due to the extremely high memory require-
ments (> 1 TB of RAM). The physical dimensions of the
simulated domain were kept constant as described in Sec-
tion 2.B. For each simulation the five final cycles of the
pressure were extracted at the focal-point. The pressure
time-series was then used to evaluate the frequency spec-
trum and the intensity at the focal-point. The results from
the homogeneous convergence test are presented in Fig. 3
(analogous behavior was observed for the heterogeneous
set of simulations).
As shown in Fig. 3, by increasing the grid-size, a higher
number of harmonics is supported and the effects of non-
linear propagation are more accurately captured. At the
lowest grid-size S1 only the fundamental frequency is sup-
ported, thus, the pressure waveform is a pure sinusoid but
with a reduced amplitude. As the grid-size increases, the
higher frequencies supported capture the nonlinear steepen-
ing of the wave and the amplitude of the pressure wave-
form increases. As the grid-size increases the pressure
waveform also converges. Beyond the 6th harmonic
(24 MHz), which is close to the maximum frequency sup-
ported by S4, the amplitude of the higher harmonics
becomes extremely small in comparison to the fundamental
frequency. Also, the intensity at S5 changes only by 1.79%
from its value at S4. On the other hand, the computational
cost increases dramatically when switching to S5 ( 7 days
vs.  2 days) making multiple simulations impractical even
on the large computing cluster used for this study. Having
in mind the trade-offs described here, the remaining simu-
lations were performed at S4. It is noted that, with more
than 10 billion grid points, the simulation at S5 is one of
the largest ultrasound simulations of its kind performed to
date.52
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2.F. Simulation deployment
The simulations were performed using the MPI version of
k-Wave52,53 on the IT4Innovations’ Salomon HPC based at
the National Supercomputing Center at VSB-Technical
University of Ostrava in the Czech Republic. The actual hard-
ware utilized for each simulation comprised of 144 cores and
768 GB of RAM (6 nodes with two Intel Xeon E5-2680v3
processors, each equipped with 24 cores and 128 GB RAM,
interconnected by a 7D Enhanced hypercube Infiniband net-
work). For the S5 simulation, 9 nodes were utilized. Table I
summarizes the memory and simulation-time requirements
for a single homogeneous and heterogeneous simulation at
each grid-size. At S4, the output of a single heterogeneous
simulation was 445.9 GB. With a total of 143 marker posi-
tions tested, the simulations generated  63 TB of output
data and required  5 million core-hours to run. After the
completion of the simulations, the output data was processed
in Matlab to evaluate the various metrics quantifying the
effect of the marker as described in Section 2.D.
3. SIMULATION
A total of 143 marker positions were simulated: 113 with a
spherical marker and 30 with a cylindrical marker at three
orientations. Figure 4 provides a visual description of the
simulations performed to determine the marker effect on the
HIFU beam. Figure 4(a) shows the maximum pressure field
as recorded across the whole domain when the HIFU beam
propagates in a homogeneous medium. The inset is a visual-
ization of the 6 dB focal volume. The metrics extracted
from this simulation serve as a reference for comparison to
assess how placing a marker in the path of the beam deterio-
rates the focusing. Figure 4(b)–4(d) demonstrate how the
maximum pressure field and the focal volume changes when
a marker is introduced and gradually moved away from the
focal-point. Figure 4(b) shows the dramatic effect of the mar-
ker when placed very close to the focal-point, while Figs.
4(c)–4(d) illustrate how the marker effect decreases as its dis-
tance from the focal-point increases. Finally, Fig. 4(d) shows
that beyond a certain distance, focusing is re-established with
the marker effect becoming less pronounced.
The metrics extracted for each marker position can be used
to quantitatively study the marker’s effect. Figures 5 and 6
show the evaluated metrics for the spherical and cylindrical
gold markers respectively. For both sets of plots, the metrics
are plotted along the axes connecting the focal-point to the
transducer. The metrics are plotted with respect to the dis-
tance of the marker from the focal-point, with the positive
direction indicating that the marker is positioned toward the
transducer.
Figures 5(a) and 5(b) show how the intensity (which is
proportional to the rate of heat deposition) changes with mar-
ker position at the maximum-pressure point (mmax) and at the
focus (mref ), respectively. When the spherical marker is posi-
tioned very close to the focus, the intensity reduces dramati-
cally. However, as the marker moves away from the focal-
point and towards the transducer, the intensity increases. As
an indication, at 11.5 mm and 8.5 mm the intensity at the
focal-point is reduced by 10% and 20% respectively. Moving
the marker further away from the focus, both intensities con-
tinue to gradually increase and eventually converge to approx-
imately Ihom, indicating that focusing has been re-established
fully.
A slightly different behavior is observed when the marker
is positioned at exactly the focus (mref ) of the transducer. It is
clear from Fig. 5(b) that practically no energy reaches the
intended focal position. On the other hand, Fig. 5(a) shows
that the maximum intensity more than doubles due to the
reflections caused by the marker, which redirect the energy to
the pre-focal region. This is due to the large impedance differ-
ence between the background medium (prostate) and the
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FIG. 4. Maximum pressure field of (a) a homogeneous simulation and (b)–(d) three heterogeneous simulations for three marker positions. The insets have dimen-
sions 39398 mm and are visualizations of the 6 dB focal-volume (dashed outline) evaluated using Eq. (4) and the spherical marker (solid-line circle). For each
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marker is inside the region indicated by the dashed line, the intensity at the focus drops by more than 30%. [Color figure can be viewed at wileyonlinelibrary.com]
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marker (gold), which results in a high reflection coefficient
(R = 0.91). When the marker is gradually shifted in the nega-
tive direction, the intensity at the maximum Imax and the
focus Ifocus quickly converge to the homogeneous value Ihom
with no significant reflections observed beyond approxi-
mately 4 mm.
Figure 5(d) illustrates the effect of the marker on the
position of the maximum pressure (mmax) relative to the
focal-point (mref ). When the marker is positioned at a dis-
tance between 4 mm and 8 mm from the focal-point, a
shift in the focus is observed of up to approximately 5.5
mm. The distortion caused by the marker can also be
observed by looking at the variation in the size of the focal
volume in Fig. 5(e) and the insets in Fig. 4. When the mar-
ker is placed at a distance from the focus between 4 mm
and 8 mm, the focal volume decreases as its position
moves closer to the focal-point, indicating its negative
effect on the beam. The markers placed along the four
outer radial axes seem to diverge from this behavior. As
those markers move towards the focus from the positive
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FIG. 5. Metrics quantifying the effect on the HIFU beam of a 3 mm gold spherical marker. All the metrics, except in (c), are plotted with respect to marker
distance from the focus, with each curve corresponding to one of the radial axes shown in the inset of (f). The horizontal dotted line corresponds to the
respective metric value obtained from a homogeneous simulation. (a) and (b) show respectively the intensity evaluated using Eq. (3) at the maximum-pres-
sure point (mmax) and at the focus (mref ), with the solid-line in (b) showing the intensity as predicted by the geometric model in Eq. (5). (d) shows how
the distance between mmax and mref changes as calculated with Eq. (2). (e) is the focal-volume with marker position as given by Eq. (4) and (f) is the ratio
between the second (V2) and first (V1) largest volumes in the focal region. Finally, (c) shows the intensity at the focus but plotted against the angle (ϑ)
between the central radial axis and the axis on which the marker lies. Here, each curve corresponds to the group of markers at a constant distance from the
focus as indicated in the inset. [Color figure can be viewed at wileyonlinelibrary.com]
Marker Distance [mm]
I f
o
c
u
s
[k
W
/c
m
2
]
0
0.2
0.4
0.6
0.8
1
1.2
Marker Distance [mm]
F
o
c
u
s
 S
h
if
t 
[m
m
]
0
0.5
1
1.5
2
Marker Distance [mm]
0 10 20 30 40 0 10 20 30 40 0 10 20 30 40
F
o
c
a
l 
V
o
lu
m
e
 [
m
m
3
]
0
0.1
0.2
0.3
0.4
0.5
(a) (b) (c)
FIG. 6. Metrics quantifying the effect on the HIFU beam of a 391 mm gold cylindrical marker at different orientations. All the metrics, are plotted with respect
to marker distance from the focus, with each curve corresponding to one of the orientations shown in the inset of (b). The horizontal dotted line corresponds to
the respective metric value obtained from a homogeneous simulation. (a) is the intensity at the focus (mref ) given by Eq. (3), with the solid-lines showing the
intensity as predicted by the geometric model in Eq. (5) for each orientation. (b) is the change in the distance between mmax and mref evaluated using Eq. (2) and
(c) is the focal-volume with marker position as given by Eq. (4). [Color figure can be viewed at wileyonlinelibrary.com]
Medical Physics, 44 (2), February 2017
686 Georgiou et al.: Effect of ﬁducial markers on HIFU 686
direction, the decrease in focal volume is first preceded by
a sharp increase. This is likely due to refocusing caused by
reflections and diffraction around the marker. Moving the
marker beyond 4 mm and 8 mm causes the focal volume
to gradually converge back to its homogeneous value, indi-
cating that focusing is re-established.
Placing the marker close to the focus also causes the focal-
volume to split from a single region [Fig. 4(a)] into multiple
smaller volumes of high pressure [Fig. 4(b)], which may
induce heating at undesired locations. Figure 5(f) shows the
ratio between the second (V2) and first (V1) largest connected
components of the 6 dB volumes for each marker position.
The ratio between the two volumes increases as the marker is
positioned closer to the focus. When the marker is placed
away from the focal-point the size of V2 reduces to zero
demonstrating that any secondary regions of high pressure
are eliminated.
Figure 5(c) offers an alternative perspective on the effect
of the marker on the intensity at the focus. In this case, the
markers are grouped together with respect to their distance
from the intended focus. Therefore, each curve corresponds
to a fixed distance from the focus. The intensity is plotted
with respect to the angle between the z-axis passing
through the focus and the radius connecting the center of
the marker with the focus. The markers outside the HIFU
beam are denoted with squares whereas those inside the
beam are denoted with dots. This plot shows that, as long
as the marker is positioned inside the HIFU beam, its effect
on the intensity remains approximately the same when its
distance from the intended focus is kept constant. The fig-
ure also demonstrates the large reduction in intensity due
to the markers closer to the focus (positive angles), how-
ever, as the angle increases, their effect on the intensity
reduces since they move outside the HIFU beam. For the
markers beyond the focus (negative angles), a small
increase in intensity can be seen which reduces as their dis-
tance from the focus increases in the negative direction.
The analogous behavior is observed for the focus shift and
focal volume.
To investigate the effect of marker shape, another set of
simulations was performed using a single gold cylindrical
marker. A total of 30 simulations were executed: 10 marker
positions were simulated along the z-axis passing through the
focal-point with 3 orientations for each position as shown in
Fig. 2(b)–2(d). The orientation in Fig. 2(b) is the most likely
to be encountered in practice because of the procedure with
which the markers are inserted. The simulations were
restricted to a single radial axis in order to limit the number
of simulations executed. This restriction was justified based
on the observation that the effect of the spherical marker
remains constant at a fixed distance from the focal-point as
demonstrated in Fig. 5(c).
For each position of the cylindrical marker, the same set of
metrics were calculated. Comparison of the plots in Fig. 6
with the corresponding plots in Fig. 5 suggests that the cylin-
drical marker distorts the HIFU beam in the same manner as
the spherical marker. Namely, as the marker moves closer to
the focal-point, the intensity and focal-volume decrease while
the shift in the focus increases. It is also interesting to observe
that marker orientation has an effect. For example, in terms
of the intensity at the focal-point, the orientation parallel to
the beam’s axis has the smallest impact since the surface area
encountered by the wave is the smallest, but it has the largest
focus shift since the maximum pressure point occurs close to
the base of the marker furthest from the focus. For the
remaining two orientations, the metrics in Fig. 6 vary in a
similar manner. This is likely due to their projected areas on
the HIFU beam being similar.
4. GEOMETRIC MODEL
The results discussed above suggest that the distortion
introduced by the marker is dominated by strong reflections.
This is not surprising due to the large density difference
between the background medium and gold, which results in a
high reflection coefficient at the interface of the two materi-
als. Additionally, the impact of the different marker orienta-
tions suggests a dependence on the surface area of the marker
encountered by the wave. Based on these observations and
with the aim of providing a faster and more efficient method
for estimating the effect of different markers, a simple analyti-
cal model was derived which evaluates the focal intensity by
considering the effect of a single marker.
Figure 7 defines the various parameters of the model
assuming a spherical marker. More specifically, it shows the
HIFU beam of the geometric model (solid-yellow line),
whose size is determined by the focal length of the transducer
Rt, its width Wt and its length Lt. Figure 7 also shows a
cross-section of the beam with a spherical-strip shape (solid-
green line), which is tangential to the point on the marker fur-
thest from the focus. The cross-section has a length Lw and
width Ww with a radius Rw. The circle indicates a cross-sec-
tion of the spherical marker with diameter d and its center at
a distance r from the focal-point. It is noted that, although a
spherical marker is considered as an example here, the model
can be adapted to any other shape.
With reference to Fig. 7, let Ihom denote the intensity at the
focal-point of an uninterrupted beam (evaluated from a
homogeneous simulation), Aw the total area of the beam’s
cross-section and Am the projected area of the marker on the
cross-section (red-solid line). Then, the intensity at the focus
(mref ) when the beam is obstructed by a marker is approxi-
mately given by
Ifocus  Ihom 1
Am
Aw
 
: (5)
The values of Am and Aw vary according to the distance of the
marker from the focal-point. Additionally, Am changes
depending on the marker’s shape and its orientation. Thus,
evaluating Eq. (5) requires a single homogeneous simulation
to obtain Ihom and then calculation of the areas Am and Aw.
This is a significant improvement in terms of computation
time since, after obtaining Ihom from a single homogeneous
simulation, the time required for evaluating Eq. (5) is
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negligible compared to simulations. The model omits wave
propagation due to diffraction or refraction and accounts only
for perfect reflection. It also assumes that the energy lost only
depends on the shape of the marker, its distance from the
transducer’s focus and the shape of the cross-section of the
beam tangential to the marker.
The total area of the beam’s cross-section Aw can be
approximated as the area of a sector of a spherical strip
Aw ¼ hRwWw (6)
where h is the angle defining the sector of the strip in radians,
Ww is the width of the strip and Rw is the radius of the sphere
on which the strip lies. As shown in Fig. 7, in this example
h ¼ 2 arcsinðLt=ð2RtÞÞ and Rw ¼ r þ d=2, since a
spherical marker is assumed here, and Ww ¼ RwWt=Rt
¼ ðr þ d=2ÞWt=Rt. Substituting in Eq. (6) yields
Aw ¼
2Wtðr þ d=2Þ
2
arcsinðLt=ð2RtÞÞ
Rt
: (7)
Calculating Aw for a different marker shape only requires
obtaining a value for Rw with the rest of the steps remaining
unchanged.
For a spherical marker, its projected area Am on the tan-
gential cross-section of the beam, as indicated in Fig. 7 (red-
solid line), has a spherical-cap shape whose surface area is
given by
Am ¼ 2pRwhc (8)
where Rw is the radius of the sphere on which the spherical
cap lies and hc is the cap’s height. In this example,
Rw ¼ r þ d=2 as explained above and hc ¼ Rw  Rw
cos/, where / = arcsin(d/(2r)). Substituting in Eq. (8) then
gives
Am ¼ 2p r þ
d
2
 2
1 cos arcsin
d
2r
   
: (9)
Analogous arguments hold for evaluating the projected area
Am for the cylindrical marker, or any other marker shape.
The effect of both the spherical and cylindrical marker
on the intensity at the focal-point as predicted by Eq. (5) is
compared with the simulation results in Figs. 5(b) and 6(b)
respectively (denoted by the solid-lines). To quantify the
agreement of the model with the simulated intensity at the
focus (Ifocus), the root-mean-square relative error (RMSRE)
was evaluated along the beam axis to which the other axial
responses converge to and it is shown in Table II. The
model slightly underestimates the marker’s effect and
becomes less accurate for marker positions closer to the
focus, but overall it confirms the assumption that
TABLE II. Exclusion zone radius evaluated using the geometric model
defined in Eq. (5) for different types of markers and orientations.
Marker type
Dimensions
(mm)a
Orientation
(degrees)b
Distance
(mm)c
RMSRE
(%)d
Spherical 1 — 2.3 —
Spherical 2 — 4.5 —
Spherical 3 — 6.8 15.7
Cylindrical 391 0 5.0 8.1
Cylindrical 391 45 5.7 18.2
Cylindrical 391 90 5.3 22.8
aDimensions are: diameter for spherical marker, height 9 diameter for cylindrical
marker.
bAngle measured on xz plane between the central radial axis connecting the focus
to the transducer and the symmetry axis of the cylinder.
cThe distance from the focal-point towards the transducer at which the intensity
drops by 30%, which is equivalent to approximately a 50% reduction in lesion
volume, calculated using Eq. (5).
dRoot-mean-square relative error (RMSRE) of the intensity at the focus (Ifocus)
between the simulated values along the beam axis and those evaluated using the
geometric model.
Beam cross-
section
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Focus
Beam
Beam cross-
section
(a)
Marker
Focus
Beam
Beam cross-section
(b)
(c)
FIG. 7. The parameters of the geometric model defined in Eq. (5) assuming
a spherical marker. The parameters are shown on (a) the xz, (b) the yz and (c)
xy planes. [Color figure can be viewed at wileyonlinelibrary.com]
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reflections are the dominating effect causing the observed
distortion. This suggests that Eq. (5) can be used to
approximate the marker effect for arbitrary shapes without
the necessity of performing time-consuming and
computationally intensive simulations.
Table II provides an indicative list of distances from the
focal-point at which the intensity drops by 30%, which is
equivalent to approximately a 50% reduction in lesion vol-
ume, for different dimensions of cylindrical and spherical
markers. The listed distances were evaluated using the analyt-
ical model in Eq. (5). Considering that the effect of a marker
within the ultrasound beam remains the same at a fixed dis-
tance from the focal-point, Table II may be used to define a
region around the focal-point within which the marker’s
impact on the beam is significant and thus may affect the
delivery of the HIFU treatment. An example of such an exclu-
sion zone is shown in Fig. 4(a) for the 3 mm spherical mar-
ker, where the radius of the exclusion zone from the focus
was extracted from Table II and its lateral width was evalu-
ated using four times the beam width (4 1:41c0=f0Rt=Lt
 2:6 mm). The region defined by these boundaries may be
used to evaluate whether a particular region in the prostate
can be effectively treated using transrectal HIFU when a mar-
ker obstructs the beam.
5. CASE STUDIES
The results presented in the previous sections suggest
that the marker distorts the HIFU beam with its effect
increasing the closer it is positioned to the focus. To exam-
ine how these results might be applied in a clinical setting,
four datasets have been retrospectively selected of patients
with recurrent prostate cancer after failed EBRT, which
were eligible for salvage-HIFU at UCLH. Three cases were
selected in which the presence of the marker may affect the
treatment and one case in which the marker is not expected
to impose any risk. As shown in Fig. 8, for each patient
three images from different modalities are presented co-
registered. In each of these images, a contour identifies the
region targeted during the treatment and a dot indicates the
assumed position of a 391 mm cylindrical marker. Due to
the difficulty in locating the exact marker position of the
medical images, the marker positions were added in soft-
ware retrospectively based on standard insertion protocols.
The outline of the exclusion zone is also shown with its
radius extracted from Table II for the cylindrical marker at
45 and its orientation determined by the likely direction of
propagation of the HIFU beam indicated by the dashed
line. Table III provides details of the four case-studies
including the post-operative outcome with regards to any
recurrence and its position for comparison with the
modelled outcome.
For the first patient, the marker is close to the rectal
wall and inside the region targeted during the treatment.
Having in mind the strong reflections induced when posi-
tioned close to the focus, the marker may cause two side-
effects. Firstly, the reflected wave may cause secondary
regions of high pressure on the rectal wall, and secondly,
the region in the top part of the exclusion zone may not
receive enough energy to be adequately treated. Reviewing
the patient’s post-operative outcome confirmed (Table III),
a recurrence in the lateral position of the lesion consistent
with possible disruption from the position of the fiducial
marker. In the second example, the marker is positioned
near the upper edge of the region to be treated. In this
case, the reflections due to the marker may cause exces-
sive heating of regions in the bottom part of the exclu-
sion zone, although this is unlikely to affect overall
treatment efficacy. The clinical outcome was once again
consistent with the modelling outcome. Although the
patient developed a recurrence it was in the midline, some
distance away from the marker, and thus the recurrence is
likely due to either an inadequate surgical margin taken
during the HIFU treatment or due to incomplete cell kill.
The third patient, demonstrates another extreme case in
which the marker is positioned near the lower bound of
the treatment area. Here the reflected wave may induce
heating in areas outside the desired treatment region
within the bottom part of exclusion zone and leave the
top part of the exclusion zone inadequately treated. In this
case, recurrence of the tumor was again observed which,
although not entirely in the predicted field of recurrence,
it may have been influenced by the presence of the mar-
ker. In the final example, the marker is positioned away
from the intended treatment region, thus, it is not
expected to affect the treatment. This is confirmed by the
post-HIFU MRI with no residual tumor within the treat-
ment zone.
6. SUMMARY AND DISCUSSION
Gold fiducial markers are commonly used as part of the
IGRT procedure during EBRT for men with localized or
locally advanced prostate cancer. These markers remain per-
manently implanted in the prostate. Thus, they may affect
the efficacy and safety of the subsequent use of HIFU
treatment as a salvage therapy in case of local cancer recur-
rence. This work investigated the impact on the HIFU
beam of a single spherical or cylindrical gold fiducial mar-
ker through a series of simulations performed using the
open-source k-Wave Toolbox. For each marker configura-
tion, four metrics were evaluated to quantify its impact on
the beam. By comparing these metrics with their corre-
sponding values from a homogeneous simulation, it is evi-
dent that the distortion introduced by the marker increases
as its distance from the transducer’s focus decreases and
depends on the marker’s shape.
Assuming perfect reflections, an analytical model was
developed based on geometric arguments, which estimates
the impact of the marker on the intensity at the focus. Using
the model, which is in good agreement with the simulated
results, it is possible to identify the boundaries of a region
around the focus within which the presence of a marker will
lead to an intensity drop below an acceptable threshold. For
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(a) (b) (c)
(d) (e) (f)
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FIG. 8. Diagnostic images of four prostate-cancer patients. From left to right, the images are T2-weighted, apparent diffusion coefficient (ADC), and dynamic-
contrast enhanced (DCE) magnetic resonance images (MRI). For each patient the three images are co-registered and show the targeted treatment region (solid-
line contour), the position of a 391 mm cylindrical gold marker (dot marker), the exclusion zone (dashed outline) for a cylindrical marker at 45 and the direction
of propagation of the HIFU-beam (dashed straight line). The exclusion zone is positioned such that the focus of the transducer coincides with the position of the
marker and it is aligned with the direction of propagation of the HIFU beam. [Color figure can be viewed at wileyonlinelibrary.com]
TABLE III. Clinical characteristics of the patients with recurrent prostate cancer after failed EBRT included in the case study.
Case Cancer stage Locationa
Lesion
volume Salvage HIFU treatment plan Outcome
Possible
marker effect
Case 1 Intermediate risk Gleason
3+4 prostate cancer
Right PZ apex 1 cc Quadrant ablation, 4 cm and 3 cm blocks Infield failure - lateral
recurrence
Yes
Case 2 Intermediate risk Gleason
3+4 prostate cancer
Left PZ mid to
apex extending
across midline
2.3 cc Extended left hemi-ablation HIFU infield failure -
midline recurrence at edge
of treatment zone
No
Case 3 Intermediate risk Gleason
3+4 prostate cancer
Right PZ 1.1 cc Right subtotal hemi-ablation
in 4 cm, 3 cm and 3 cm blocks
Infield failure at site
of marker
Yes
Case 4 Intermediate risk Gleason
3+4 prostate cancer
Right anterior TZ 0.8 cc Right quadrant ablation
in 4 cm and 3 cm blocks
No recurrence No
aPZ: peripheral zone, TZ: transitional zone.
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example, as shown in Table II, placing a 391 mm marker
within approximately 5 mm of the focus in the pre-focal
region will induce an intensity drop of more than 30% of the
homogeneous value, which will cause a reduction in the vol-
ume of the ablated region. As examined in Fig. 8 using scans
of prostate cancer patients, this region around the marker can
be divided into two parts: an undertreated region due to less
energy arriving above the focus and an overtreated region due
to reflections below the focus. Both effects may be undesir-
able depending on the location of the marker. Moreover, there
is evidence that the region of recurrence after EBRT is the
main tumor (index lesion).54 Therefore, the results of this
study may justify avoiding the index lesion during fiducial
marker placement. Although a degree of accuracy was
observed between the position of the marker and the site of
recurrence, the cohort consisted only of four patients, thus
extracting firm conclusions is difficult. Further work using
larger retrospective and prospective cohorts is necessary to
further develop and validate the model to allow its utilization
in clinical practice. Such a study will aim to reveal the per-
centage of affected patients by the results of this study and
whether the marker’s impact can justify the exclusion of some
patients from salvage-HIFU or the revision of the placement
protocol of fiducial markers during EBRT. Experimental
measurements on ex vivo tissue phantoms with implanted
markers are also needed to confirm these results.
While investigating the distortion introduced by the mar-
ker, the study has omitted some additional factors which
may affect the significance of the marker’s impact on the
treatment. Firstly, as discussed in Section 2.A., the Sonab-
late 500 probe, on which the transducer model was based,
includes an imaging transducer which was not taken into
account in the simulations. Although this is expected to
affect the intensity at the focus (for the same source surface
intensity), it is unlikely to change the distortion introduced
by the marker. Similarly, since the operation of the other
existing transrectal and transurethral HIFU systems is based
on the same principles, using a different transducer model is
not expected to affect the behavior of the marker observed
here. Second, only the effect on the intensity at the focus
(which correlates with heating rate) has been investigated.
However, in practice, additional heating may occur due to
absorption within the marker and viscous relative motion
between the marker and surrounding tissue. These effects,
combined with the multiple sonications used during a treat-
ment, may help to counteract the reduced heating due to the
lower intensity. It is also unclear from this work whether
cavitation, which is triggered by large negative pressures, is
reduced due to the presence of the marker. Finally, although
other types of markers exist (see Section 1), only gold mark-
ers have been considered. However, given that all the materi-
als used have greater impedance than the prostate, using
other types of markers is unlikely to change the behavior
observed here. A scenario in which the treatment may be
severely affected is when a large number of marker-like ele-
ments are introduced in the prostate. Such a situation occurs
during salvage-HIFU after failed (low-dose) brachytherapy,
where a large number of seeds are permanently implanted in
the prostate. Extending the insights of this work for the
brachytherapy case and exploring other factors which may
affect the distortion introduced by the marker, will be the
subject of future work.
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